Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation II

ABSTRACT: Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation II

PROVIDER: PRJNA487073 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7731421_1.fastq.gz	Fastqsanger.gz
	SRR7731421_2.fastq.gz	Fastqsanger.gz
	SRR7731422_1.fastq.gz	Fastqsanger.gz
	SRR7731422_2.fastq.gz	Fastqsanger.gz
	SRR7731423_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 18

Similar Datasets

Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma engages the ER-stress response I

Project description:The purpose of this study was to define biomarkers of sensitivty and mechanisms of resistance to the KDM1A/LSD1 inhibtor SP-2509 (HCI-2509) in Ewing sarcoma cell lines. We report that regardless of drug sensitivity all cell lines engage the UPR and ER-stress response following treatment with SP-2509 resulting in apoptotic cytotoxicity. In addition hypersentsitive cell lines shared a common basal transcriptnomic profile, with hypersensitive cell lines signficantly inducing ETS1 which was not observed in sensitive cell lines.

2019-05-03 | GSE98785 | GEO

Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma engages the ER-stress response II

Project description:The transcriptional profile of LSD1 knockdown in A673 Ewing sarcoma cells mirrors that of EWS/FLI knockdown and LSD1 small molecule inhibition (SP-2509)

2019-05-03 | GSE98786 | GEO

Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation

Project description:Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation

| PRJNA487068 | ENA

Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation I

Project description:Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation I

| PRJNA487071 | ENA

Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation I

Project description:The transcriptional profile of A673 parental and SP-2509 Drug resistant cells treated with DMSO and SP-2509 (2uM 48hrs)

2018-12-26 | GSE118864 | GEO

Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation II

Project description:The transcriptional profile of A673 parental, and SP-2509 drug resistant washout cells (4 and 6 months)

2018-12-26 | GSE118870 | GEO

Ewing sarcoma resistance to SP-2509 is not mediated through KDM1A/LSD1 mutation.

Project description:Ewing sarcoma is the second most common solid bone malignancy diagnosed in pediatric and young adolescent populations. Despite global co-operative efforts, outcomes for patients with relapsed and refractory disease remains obstinately poor. It has become increasingly clear that disruption of the epigenome as a result of alterations in epigenetic regulators, plays a pivotal role in tumorigenesis. As such, this study investigated Ewing sarcoma mechanisms of acquired resistance to the small molecule reversible lysine specific demethylase (LSD1/KDM1A) inhibitor SP-2509. Surprisingly, whole exome sequencing analysis of our generated A673 SP-2509 drug resistant cell line revealed an absence of mutations in KDM1A. Compared to parental counterparts, SP-2509 drug resistant cells demonstrated decreased anchorage independent growth capacity, enhanced sensitivity to the HDAC inhibitors vorinostat/entinostat and a distinct transcriptional profile that was enriched for extracellular matrix proteins. SP-2509 drug resistant cells also exhibited elevated expression levels of the multi-drug resistance genes ABCB1, ABCC3, and ABBC5 and decreased expression of the transcriptional repressor RCOR1/CoREST. Following several months of SP-2509 withdrawal, low level SP-2509 resistance was still apparent (6.3 fold increase in IC50), with drug resistant cell populations maintaining their distinct transcriptional profile. Furthermore, compared to parental cells, washout drug resistant lines displayed equal sensitivity to the standard Ewing sarcoma chemotherapeutic agent's vincristine and doxorubicin. Together these findings indicate that resistance to SP-2509 is not fully reversible or driven by direct mutation in KDM1A.

| S-EPMC6284858 | biostudies-literature

Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma engages the ER-stress response

Project description:Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma engages the ER-stress response

| PRJNA386197 | ENA

RNA sequencing of A673 and monoclonal KO cells treated with DMSO or SP-2509

Project description:RNA sequencing data for a Ewing sarcoma cell line, A673 treated with DMSO or the LSD1 inhibitor, SP-2509. Monoclonal cell lines were generated by CRISPR/Cas9 mediated KO of mitochondrial genes MRPL45, UQCRFS1, and CYC1. These cells were treated with DMSO or SP-2509 to determine mitochondrial gene KO derived drug resistance.

2022-04-05 | GSE185379 | GEO

Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.

Project description:Multi-agent chemotherapeutic regimes remain the cornerstone treatment for Ewing sarcoma, the second most common bone malignancy diagnosed in pediatric and young adolescent populations. We have reached a therapeutic ceiling with conventional cytotoxic agents, highlighting the need to adopt novel approaches that specifically target the drivers of Ewing sarcoma oncogenesis. As KDM1A/lysine-specific demethylase 1 (LSD1) is highly expressed in Ewing sarcoma cell lines and tumors, with elevated expression levels associated with worse overall survival (P = 0.033), this study has examined biomarkers of sensitivity and mechanisms of cytotoxicity to targeted KDM1A inhibition using SP-2509 (reversible KDM1A inhibitor). We report, that innate resistance to SP-2509 was not observed in our Ewing sarcoma cell line cohort (n = 17; IC50 range, 81 -1,593 nmol/L), in contrast resistance to the next-generation KDM1A irreversible inhibitor GSK-LSD1 was observed across multiple cell lines (IC50 > 300 μmol/L). Although TP53/STAG2/CDKN2A status and basal KDM1A mRNA and protein levels did not correlate with SP-2509 response, induction of KDM1B following SP-2509 treatment was strongly associated with SP-2509 hypersensitivity. We show that the transcriptional profile driven by SP-2509 strongly mirrors KDM1A genetic depletion. Mechanistically, RNA-seq analysis revealed that SP-2509 imparts robust apoptosis through engagement of the endoplasmic reticulum stress pathway. In addition, ETS1/HIST1H2BM were specifically induced/repressed, respectively following SP-2509 treatment only in our hypersensitive cell lines. Together, our findings provide key insights into the mechanisms of SP-2509 cytotoxicity as well as biomarkers that can be used to predict KDM1A inhibitor sensitivity in Ewing sarcoma. Mol Cancer Ther; 17(9); 1902-16. ©2018 AACR.

| S-EPMC6201274 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data